Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines

Pathobiology

Volumn 75, Issue 4, 2008, Pages 244-251

  Jiang, Ying ^a   Tong, Dandan ^a   Lou, Ge ^a   Zhang, Ying ^a   Geng, Jingshu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Methylation; Prognosis; RUNX3 gene

Indexed keywords

BETA ACTIN; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST FIBROADENOMA; CANCER CELL CULTURE; CANCER GRADING; CANCER INFILTRATION; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX3 GENE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FIBROADENOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 46349102935     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132385     Document Type: Article

References (26)

1. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y: Interaction and functional cooperation of PEBP2/CBF with Smads: synergistic induction of the immunoglobulin germline Cα promoter. J Biol Chem 1999;274:31577-31582.
2. Okuda T, van Dursen J, Hiebert SW, Grosveld G, Downing JR: AML1, the target of multiple chromosomal translocation in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-330.
3. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-1064.
4. Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G: Missense mutations abolishing DNA binding of the osteoblastspecific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997;16:307-310.
5. Weinstein M, Yang X, Deng C: Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 2000;11:49-58.
6. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-124.
7. Bae SC, Ogawa E, Maruyama M, Oka H, Satake M, Shigesada K, Jenkins NA, Gilbert DJ, Copeland NG, Ito Y: PEBP2aB/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol 1994;14:3242-3252.
8. Schwab M, Praml C, Amler LC: Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 1996;16:211-229.
9. Suzuki M, Toyooka S, Miyajima K, Iizasa T, Fujisawa T, Bekele NB, Gazdar AF: Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res 2003;9:5636-5641.
10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
11. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-6380.
12. Weith A, Brodeur GM, Bruns GA, Matise TC, Mischke D, Nizetic D, Seldin MF, van Roy N, Vance J: Report of the second international workshop on human chromosome 1 mapping 1995. Cytogenet Cell Genet 1996;72:114-144.
13. Fang W, Piao Z, Buyse IM, Simon D, Sheu JC, Perucho M, Huang S: Preferential loss of a polymorphic RIZ allele in human hepatocellular carcinoma. Br J Cancer 2001;84:743-747.
14. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004;23:6736-6742.
15. Xiao WH, Liu WW: Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004;10:376-380.
16. Hiramatsu T, Osaki M, Ito Y, Tanji Y, Tokuyasu N, Ito H: Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology 2005;72:316-324.
17. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-174.
18. Eng C, Herman JG, Baylin SB: A bird's eye view of global methylation. Nat Genet 2000;24:101-102.
19. Lee S, Kim WH, Jung HY, Yang MH, Kang GH: Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161:1015-1022.
20. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
21. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-4053.
22. Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF: Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-616.
23. Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB, Park JG: Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer 2002;87:187-193.
24. Yang Q, Kieman CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL: Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191-3197.
25. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006;66:6512-6520.
26. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005;65:7743-7750.